Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Clinical · Molecular biology · Bioinfo & AI

Graph neural network-based risk stratification of prostate cancer using gene expression and SHAP interpretability

Summary

This study introduces an artificial intelligence framework utilizing graph neural networks (GNNs) for prostate cancer risk stratification, integrating mRNA expression profiles with functional interaction networks. The aim is to classify patients into low-, medium-, and high-risk groups, defined by Gleason scores, to guide treatment decisions and prevent overtreatment. Developed using TCGA data, the model achieved an overall accuracy of 80% and high AUCs on an independent test set. Differentially expressed genes were identified for each risk group, highlighting the molecular heterogeneity of disease progression.

Critical appraisal

Clinical. This AI framework aims to improve prostate cancer risk stratification, a critical step to prevent overtreatment and biopsy-related complications. By offering a potentially less invasive risk assessment based on gene expression, it could justify phase II/III clinical trials to validate its utility as a prognostic or predictive biomarker. If validated, this could alter clinical practice by enabling more personalized treatment decisions and potentially reducing the need for invasive biopsies, with a potential clinical impact in 5+ years.

Molecular biology. The study identified differentially expressed genes (e.g., ASPN, GMNN, PEBP4 for high-risk; TNMD, VWA5B2 for low-risk) that underpin the molecular heterogeneity of prostate cancer. The use of mRNA expression profiles combined with functional interaction networks represents a biomarker discovery approach. The underlying technology is gene expression analysis (likely RNA-seq or microarrays, though not specified beyond "mRNA expression profiles" and "gene expression data" from TCGA). Validation of these biomarkers in external cohorts is crucial to establish their analytical and clinical validity.

Bioinfo & AI. At the core of this study is a dual-branch graph neural network (GNN) that integrates gene-gene interaction graphs with sample-level expression features. The use of SHAP for interpretability is a strength, allowing quantification of feature contributions and understanding of molecular patterns. The model achieved AUCs of 0.86, 0.88, and 0.95 for the low-, medium-, and high-risk groups respectively, with an overall accuracy of 80% on an independent test set. However, the model was developed and evaluated solely on the TCGA cohort, necessitating rigorous external validation to ensure generalizability and reproducibility before any clinical deployment.

The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology